Novartis AG is reportedly close to finalizing an acquisition of biotechnology firm Avidity Biosciences Inc., according to sources familiar with the matter. The potential deal marks a significant move for Novartis as it seeks to expand its portfolio in the biotech and gene therapy sectors.
Avidity Biosciences specializes in developing antibody-mediated delivery platforms for RNA therapies, focusing on treatments for neuromuscular and other rare diseases. The company’s innovative approach has garnered attention within the biotech industry, making it an attractive target for larger pharmaceutical companies looking to strengthen their pipeline.
While specific financial details of the proposed deal have not been disclosed, the negotiations underscore Novartis’s ongoing strategy to bolster its presence in next-generation biotechnologies. The companies are reportedly in advanced talks, with a final agreement anticipated in the coming weeks.
This potential acquisition aligns with Novartis’s broader efforts to enhance its R&D capabilities and accelerate the development of advanced therapies. If completed, the deal could represent a significant shift in the company’s biotechnological ambitions and further influence the competitive landscape of the industry.